Skip to content

TriSalus Life Sciences, Inc. TLSI Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Par or Stated Value Per Share at other companies

Boston Scientific logo
Boston ScientificBSX
InfuSystem Holdings logo
InfuSystem HoldingsINFU
Delcath Systems logo
Delcath SystemsDCTH
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share?
TriSalus Life Sciences, Inc. (TLSI) reported preferred stock, par or stated value per share of $0 in Q1 2026.
How has TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share changed year-over-year?
TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share?
Over 2 years (2023 to 2025), TriSalus Life Sciences, Inc.'s preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.